IGF-IR Targeted Therapy: Past, Present and Future

Joseph A M J L Janssen, Aimee J Varewijck

Research output: Contribution to journalReview articleAcademicpeer-review

49 Citations (Scopus)
4 Downloads (Pure)

Abstract

The IGF-I receptor (IGF-IR) has been studied as an anti-cancer target. However, monotherapy trials with IGF-IR targeted antibodies or with IGF-IR specific tyrosine kinase inhibitors have, overall, been very disappointing in the clinical setting. This review discusses potential reasons why IGF-I R targeted therapy fails to inhibit growth of human cancers. It has become clear that intracellular signaling pathways are highly interconnected and complex instead of being linear and simple. One of the most potent candidates for failure of IGF-IR targeted therapy is the insulin receptor isoform A (IR-A). Activation of the IR-A by insulin-like growth factor-II (IGF-II) bypasses the IGF-IR and its inhibition. Another factor may be that anti-cancer treatment may reduce IGF-IR expression. IGF-IR blocking drugs may also induce hyperglycemia and hyperinsulinemia, which may further stimulate cell growth. In addition, circulating IGF-IRs may reduce therapeutic effects of IGF-IR targeted therapy. Nevertheless, it is still possible that the IGF-IR may be a useful adjuvant or secondary target for the treatment of human cancers. Development of functional inhibitors that affect the IGF-IR and IR-A may be necessary to overcome resistance and to make IGF-IR targeted therapy successful. Drugs that modify alternative downstream effects of the IGF-IR, so called "biasing agonists," should also be considered.

Original languageEnglish
Pages (from-to)224
JournalFrontiers in Endocrinology
Volume5
DOIs
Publication statusPublished - 23 Dec 2014

Bibliographical note

Copyright ©2014 Janssen and Varewijck.

Funding information:
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Fingerprint

Dive into the research topics of 'IGF-IR Targeted Therapy: Past, Present and Future'. Together they form a unique fingerprint.

Cite this